Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.
Heuvelman, Valerie D
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. [electronic resource] - Cardiovascular research 04 2020 - 916-930 p. digital
Publication Type: Journal Article; Review
1755-3245
10.1093/cvr/cvz323 doi
Animals
Biomarkers--blood
Blood Glucose--drug effects
Cardiovascular Diseases--epidemiology
Cardiovascular System--drug effects
Diabetes Mellitus, Type 2--blood
Glucagon-Like Peptide-1 Receptor--metabolism
Humans
Hypoglycemic Agents--adverse effects
Incretins--adverse effects
Risk Factors
Signal Transduction
Treatment Outcome
Glucagon-Like Peptide-1 Receptor Agonists
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. [electronic resource] - Cardiovascular research 04 2020 - 916-930 p. digital
Publication Type: Journal Article; Review
1755-3245
10.1093/cvr/cvz323 doi
Animals
Biomarkers--blood
Blood Glucose--drug effects
Cardiovascular Diseases--epidemiology
Cardiovascular System--drug effects
Diabetes Mellitus, Type 2--blood
Glucagon-Like Peptide-1 Receptor--metabolism
Humans
Hypoglycemic Agents--adverse effects
Incretins--adverse effects
Risk Factors
Signal Transduction
Treatment Outcome
Glucagon-Like Peptide-1 Receptor Agonists